Immunotherapy for cancer by direct gene transfer into tumors.

16.0 Scientific Abstract The goal of immunotherapy is to stimulate the immune system by modification of tumor cells or expansion of lymphocytes which respond specifically to tumor antigens. In this...

[1]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[2]  S. Ostrand-Rosenberg,et al.  Allogeneic H-2 antigen expression is insufficient for tumor rejection. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Silverstein,et al.  BCG lmmunotherapy of Malignant Melanoma: Summary of a Seven-year Experience , 1974, Annals of surgery.

[4]  L. Lanier,et al.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis , 1986, The Journal of experimental medicine.

[5]  G. Nabel,et al.  Immunotherapy of malignancy by in vivo gene transfer into tumors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[6]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.

[7]  P. Furmanski,et al.  Spontaneous regression of Friend virus-induced erythroleukemia. III. The role of macrophages in regression. , 1978, Journal of immunology.

[8]  E. Nabel,et al.  Introduction of vascular smooth muscle cells expressing recombinant genes in vivo. , 1991, Circulation.

[9]  B. Howard,et al.  High efficiency DNA-mediated transformation of primate cells. , 1983, Science.

[10]  A. Asher,et al.  Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor. , 1992, Human gene therapy.

[11]  F. Grosveld,et al.  Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation , 1984, Nature.

[12]  P. Ralph,et al.  Role of interleukin 2, interleukin 4, and alpha, beta, and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activity , 1988, The Journal of experimental medicine.

[13]  S. Rosenberg,et al.  In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. , 1985, Journal of immunology.

[14]  L. Huang,et al.  A novel cationic liposome reagent for efficient transfection of mammalian cells. , 1991, Biochemical and biophysical research communications.

[15]  J. Watkins,et al.  Immunization of Mice against Ehrlich Ascites Tumour using a Hamster/Ehrlich Ascites Tumour Hybrid Cell Line , 1969, Nature.

[16]  E. Nabel,et al.  Site-specific gene expression in vivo by direct gene transfer into the arterial wall. , 1990, Science.

[17]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[18]  S. Segal,et al.  MANIPULATION OF METASTASIS AND TUMOUR GROWTH BY TRANSFECTION WITH HISTOCOMPATIBILITY CLASS I GENES , 1986, Journal of immunogenetics.

[19]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[20]  S. Dubinett,et al.  TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER , 1989, The Lancet.

[21]  K. Isselbacher,et al.  Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. , 1985, Science.

[22]  F. Weiner,et al.  Viral expression and immunogenicity of CBA mammary carcinomas and their hybrid lines with an L-cell derivative (A9HT). , 1979, European journal of cancer.

[23]  G. Klein,et al.  Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H. Fujiwara,et al.  The augmentation of tumor‐specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus‐reactive helper T cells , 1984 .

[25]  H. Ljunggren,et al.  EXPERIMENTAL STRATEGIES AND INTERPRETATIONS IN THE ANALYSIS OF CHANGES IN MHC GENE EXPRESSION DURING TUMOUR PROGRESSION , 1986, Journal of immunogenetics.

[26]  S. Rosenberg,et al.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 , 1985, The Journal of experimental medicine.

[27]  S. Rosenberg,et al.  IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors. , 1989, Journal of immunology.

[28]  S. Rosenberg.  Immunotherapy of cancer using interleukin 2: current status and future prospects. , 1988, Immunology today.

[29]  J. Whelan,et al.  Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. , 1983, Journal of immunology.

[30]  P. Leder,et al.  Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.

[31]  E. Nabel,et al.  Recombinant platelet-derived growth factor B gene expression in porcine arteries induce intimal hyperplasia in vivo. , 1993, The Journal of clinical investigation.

[32]  L. Old,et al.  Tumor necrosis factor (TNF). , 1985, Science.

[33]  A. Chang,et al.  Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity. , 1988, Journal of immunology.

[34]  R. Kamen,et al.  The human hematopoietic colony-stimulating factors. , 1987, Science.

[35]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[36]  L. Huang,et al.  Immunotherapy of malignancy by in vivo gene transfer into tumors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Chang,et al.  Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. , 1991, Journal of immunology.

[38]  P. Klein,et al.  VIRAL ONCOLYSIS: INCREASED IMMUNOGENICITY OF HOST CELL ANTIGEN ASSOCIATED WITH INFLUENZA VIRUS , 1967, The Journal of experimental medicine.

[39]  E. Nabel,et al.  Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. , 1992, Human gene therapy.

[40]  I. Gresser,et al.  Enhancement by interferon of the expression of surface antigens on murine leukemia L 1210 cells. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Segal,et al.  The relationship between MHC antigen expression and metastasis. , 1989, Advances in cancer research.